SNM SCANcast: GE adapts PET/CT for cardiac perfusion
From the Society of Nuclear Medicine meeting exhibit floor, an audio interview with Karthik Kuppusamy, Ph.D., general manger for Americas nuclear medicine, PET/CT, and cyclotron business at GE Healthcare, who touted the company’s Discovery VCT.
At this year's Society of Nuclear Medicine meeting, cardiac PET is emerging from the long shadow of PET/CT for oncology applications. Rejuvenated by increased Medicare reimbursements for perfusion that began this year, PET is also reaping the benefits of a growing body of research supporting its use.
On the SNM exhibit floor, Karthik Kuppusamy, Ph.D., general manger for Americas nuclear medicine, PET/CT, and cyclotron business at GE Healthcare, touted the company's Discovery VCT. The device combines 64-slice CT and high resolution PET as a one-stop shop for assessment of suspected cardiovascular disease. Discovery VCT delivers analyses of ventricular function, wall motion, and perfusion, as well as coronary CT angiograms and calcium scoring, in less than 30 minutes.
But rest and stress imaging using the Discovery VCT to identify perfusion defects presents special challenges that require the deft use of CT during pharmaceutical stress - and a special algorithm developed by GE.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
